281
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Comparative Bioavailability of Fluticasone and Azelastine Delivered as a Single Fixed Dose Combination (MP-AzeFlu) in Comparison to Two Different Formulations of Azelastine and Fluticasone Propionate Following Intranasal Administration in Healthy Chinese Volunteers

, , , , , , , & ORCID Icon show all
Pages 667-677 | Received 06 Apr 2023, Accepted 14 Jun 2023, Published online: 30 Jun 2023

References

  • Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Invest Allergol Clin Immunol. 2013;23(7):495–503.
  • Li W, Wang Y, Pei Y, Xia Y. Pharmacokinetics and bioequivalence evaluation of two montelukast sodium chewable tablets in healthy Chinese volunteers under fasted and fed conditions. Drug Des Devel Ther. 2021;15:1091–1099. doi:10.2147/DDDT.S298355
  • Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80.e73. doi:10.1016/j.jaci.2019.06.049
  • Bousquet J, Meltzer EO, Couroux P, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726–1732 e1726. doi:10.1016/j.jaip.2018.01.031
  • Bousquet J, Schunemann HJ, Fonseca J, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70(11):1372–1392. doi:10.1111/all.12686
  • Williams PB, Crandall E, Sheppard JD. Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis. Clin Ophthalmol. 2010;4:993–1001. doi:10.2147/OPTH.S13479
  • Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol. 1996;98(6):1088–1096. doi:10.1016/S0091-6749(96)80196-5
  • Berger WE, Mustakov TB, Kralimarkova TZ, Christoff G, Popov TA. Treatment with azelastine hydrochloride and fluticasone propionate in a single delivery device of young children and adolescents with allergic rhinitis. Paper presented at: Allergy Asthma Proc; 2020.
  • Mollmann H, Wagner M, Meibohm B, et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol. 1998;53(6):459–467. doi:10.1007/s002280050407
  • McKeage K, Keam SJ. Salmeterol/fluticasone propionate: a review of its use in asthma. Drugs. 2009;69(13):1799–1828. doi:10.2165/11202210-000000000-00000
  • Vicens-Artes S, Roca-Ferrer J, Tubita V, et al. Superior effect of MP-AzeFlu compared to monotherapy with fluticasone propionate or azelastine on GILZ, MKP-1 and TTP anti-inflammatory gene expression in healthy and inflamed upper airway mucosa. Clin Exp Allergy. 2022;52(6):788–791. doi:10.1111/cea.14099
  • Berger WE, Shah S, Lieberman P, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract. 2014;2(2):179–185. doi:10.1016/j.jaip.2013.09.019
  • Derendorf H, Munzel U, Petzold U, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012;74(1):125–133. doi:10.1111/j.1365-2125.2012.04222.x
  • Food and Drug Administration. Guidance for Industry Drug Interaction Studies —Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Food and Drug Administration; 2012.
  • McTavish D, Sorkin EM. Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1989;38(5):778–800. doi:10.2165/00003495-198938050-00005
  • Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1997;43(2):155–161. doi:10.1046/j.1365-2125.1997.d01-1425.x
  • Hochhaus G. New developments in corticosteroids. Proc Am Thorac Soc. 2004;1(3):269–274. doi:10.1513/pats.200402-007MS
  • Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 2003;43(1):149–173. doi:10.1146/annurev.pharmtox.43.100901.140251